Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test
Read More Pharma Industry News Memo Therapeutics secures $15.5m in Series B to propel antibody development for COVID-19 and BK virus treatment Memo Therapeutics, a Swiss biotech company, has successfully raised CHF 14 million (approximately $15.56 million) in a Series… bypharmanewsdailyNovember 8, 2020